Erythema Toxicum Neonatorum in Newborns and the Development of Asthma

Erythema Toxicum Neonatorum (ETN) is a common skin finding that affects healthy full-term babies. Several authors have commented on the possible relationship between ETN and the development of atopic conditions, such as atopic dermatitis or respiratory disease later in life. There is a paucity of research addressing this issue.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Erythema Toxicum Neonatorum Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

3 year–9 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Pediatrics, University of Rochester

Rochester, New York, 14642, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children between the ages of 3-9 years who have had at least 2 asthma diagnoses within the last 2 years.
Control subjects will be age matched and without an asthma diagnosis.

Exclusion criteria

Children without accessible medical records

Sponsors and collaborators

Lead sponsor

University of Rochester

Other

Registry information

Official study title

The Implication of Erythema Toxicum Neonatorum in Newborns on the Development of Future Asthma

Important dates

Study start: 2005
Primary completion: 2005
Study completion: 2005
First posted: Sep 15, 2005
Registry last updated: May 12, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed